Phenylpiracetam
Also known as: Phenotropil, Carphedon, Fonturacetam
Racetam Nootropic | Cognitive & Physical Performance
Overview
Phenylpiracetam (also known as Phenotropil, Carphedon, or Fonturacetam) is a phenylated derivative of piracetam developed in Russia in 1983, originally for Soviet cosmonauts to enhance cognitive function, physical stamina, and cold tolerance during space missions. The addition of a phenyl group to piracetam's pyrrolidone nucleus fundamentally changes the compound's pharmacological profile -- it crosses the blood-brain barrier more readily, has significantly greater affinity for multiple neurotransmitter systems, and exhibits pronounced psychostimulant and physical performance-enhancing properties absent in piracetam. Phenylpiracetam was approved and marketed in Russia as Phenotropil for cognitive impairment, asthenia, and convulsive disorders until its manufacturer ceased production. It gained notoriety in the sporting world after the World Anti-Doping Agency (WADA) added it to the prohibited substances list following its detection in several Olympic athletes, confirming its reputation as a legitimate performance enhancer. One of its most distinctive properties is the enhancement of cold tolerance, a trait that directly reflects its origins as a cosmonaut support compound and has been demonstrated in animal models of hypothermia.
Key benefits
- Potent cognitive enhancement including improved memory, focus, and information processing speed
- Psychostimulant properties that increase motivation, mental energy, and alertness without the jitteriness of classical stimulants
- Physical performance enhancement through improved stamina, reduced perception of effort, and increased exercise tolerance
- Enhanced cold tolerance -- a unique property among nootropics, originally developed for extreme-environment performance
- Anxiolytic effects at standard doses, reducing stress reactivity without sedation
- Anticonvulsant activity demonstrated in preclinical models
Mechanism of action
Phenylpiracetam modulates multiple neurotransmitter systems, which accounts for its broad spectrum of cognitive and physical effects. Like other racetams, it acts as a positive allosteric modulator of AMPA receptors, enhancing glutamatergic transmission and facilitating long-term potentiation in hippocampal circuits critical for memory formation. However, unlike piracetam, phenylpiracetam also significantly affects dopaminergic and noradrenergic signaling -- it increases the density of dopamine D1, D2, and D3 receptors and noradrenaline receptors in the striatum and other brain regions, which underpins its stimulant, mood-elevating, and motivation-enhancing properties. It also modulates nicotinic acetylcholine receptors and NMDA-type glutamate receptors, contributing to its procognitive effects. The phenyl group increases lipophilicity, allowing faster and more complete penetration of the blood-brain barrier compared to piracetam. Phenylpiracetam also demonstrates anticonvulsant activity and has been shown to reduce the threshold for cold-induced stress responses, likely through modulation of hypothalamic thermoregulatory circuits and peripheral adrenergic mechanisms. The compound's physical performance-enhancing effects are attributed to increased noradrenergic and dopaminergic tone, enhanced muscular endurance, and reduced perception of effort and fatigue.
Molecular data
- Type
- Racetam derivative (C12H14N2O2)
- Half-life
- ~3-5 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Cognitive Enhancement
Clinical (Approved in Russia)
Investigational / Off-Label
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100 mg | Once or twice daily (morning, or morning and early afternoon) | — |
| — | 200 mg | Single dose, 1-2 hours before event | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Insomnia, particularly if taken in the afternoon or evening -- the stimulant effects can persist for several hours after dosing
- Irritability and overstimulation, especially at higher doses or when combined with other stimulants
- Headache, most commonly caused by increased acetylcholine demand without adequate choline supplementation
- Rapid tolerance development -- the most significant practical limitation, requiring intermittent dosing schedules to maintain efficacy
Rare side effects
- Anxiety or restlessness in stimulant-sensitive individuals
- Elevated blood pressure and heart rate
- Gastrointestinal discomfort (nausea, stomach upset)
- Emotional blunting or reduced affect with chronic daily use
Contraindications
- Known hypersensitivity to phenylpiracetam or other racetams
- Severe hypertension or cardiovascular disease (due to stimulant properties)
- Pregnancy and breastfeeding (insufficient safety data)
- Severe hepatic or renal impairment
- Competitive athletes subject to WADA testing (phenylpiracetam is a prohibited substance under Section S6: Stimulants)
Monitoring
- Tolerance assessment: track subjective efficacy across days of use. If effects diminish significantly, implement a washout period before resuming
- Sleep quality: monitor for insomnia and adjust dosing time or frequency accordingly
- Blood pressure and heart rate: periodic checks recommended, especially when combining with other stimulants
- Choline status: if headaches develop, add or increase choline supplementation before adjusting phenylpiracetam dose
References
Primary literature and clinical-trial data informing this entry.